What Is the Pardes Biosciences, Inc. (PRDS) Class Action Lawsuit About?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FS Development Corp. II, which merged with Pardes Biosciences, Inc. (“Pardes” or “the Company”) (NASDAQ: PRDS) on December 27, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether FS Development Corp. II failed to provide relevant information to its shareholders before the merger.
If you are aware of any facts relating to this investigation or hold Pardes shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
How Did Pardes Biosciences, Inc. (PRDS) Stock React to the Disclosures?
How Is BG&G Representing Investors in Securities Class Actions?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”